WEBULL
WebtradeDownload

Bioscience Health Innovations Q2 FY26 turns to net loss of $185,753; revenue falls to $1.04 million

PUBT · 2d ago
Bioscience Health Innovations Q2 FY26 turns to net loss of $185,753; revenue falls to $1.04 million
  • Bioscience Health Innovations posted a net loss of $185,753 for the quarter ended June 30, 2026, swinging from net income of $457,704 a year earlier.
  • Revenue fell 41.02% to $1,036,364 on sales-channel and marketing changes, increased competition, and a rescheduled co-brand order.
  • Operating expenses rose 42.24% to $877,365, driven by senior-exchange application work, higher marketing, added R&D, wage increases, and accounting-system upgrades.
  • For the first half, net loss widened to $415,660 from net income of $884,502, while revenue dropped 38.25% to $1.79 million.
  • Management said it ended June with $712,378 in cash, completed a $1 Regulation A round, and is pursuing an uplisting while seeking up to $5 million at $4.5 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioscience Health Innovations Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001096906-26-001173), on August 07, 2026, and is solely responsible for the information contained therein.